1. Home
  2. YMAB vs SLND Comparison

YMAB vs SLND Comparison

Compare YMAB & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • SLND
  • Stock Information
  • Founded
  • YMAB 2015
  • SLND 1900
  • Country
  • YMAB United States
  • SLND United States
  • Employees
  • YMAB N/A
  • SLND N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • SLND Military/Government/Technical
  • Sector
  • YMAB Health Care
  • SLND Industrials
  • Exchange
  • YMAB Nasdaq
  • SLND Nasdaq
  • Market Cap
  • YMAB 192.4M
  • SLND 210.6M
  • IPO Year
  • YMAB 2018
  • SLND N/A
  • Fundamental
  • Price
  • YMAB $8.51
  • SLND $4.60
  • Analyst Decision
  • YMAB Buy
  • SLND Strong Buy
  • Analyst Count
  • YMAB 11
  • SLND 1
  • Target Price
  • YMAB $15.02
  • SLND $5.00
  • AVG Volume (30 Days)
  • YMAB 1.3M
  • SLND 32.8K
  • Earning Date
  • YMAB 08-08-2025
  • SLND 08-12-2025
  • Dividend Yield
  • YMAB N/A
  • SLND N/A
  • EPS Growth
  • YMAB N/A
  • SLND N/A
  • EPS
  • YMAB N/A
  • SLND N/A
  • Revenue
  • YMAB $88,658,000.00
  • SLND $931,568,000.00
  • Revenue This Year
  • YMAB N/A
  • SLND $4.47
  • Revenue Next Year
  • YMAB $15.23
  • SLND $4.30
  • P/E Ratio
  • YMAB N/A
  • SLND N/A
  • Revenue Growth
  • YMAB 4.92
  • SLND N/A
  • 52 Week Low
  • YMAB $3.55
  • SLND $1.85
  • 52 Week High
  • YMAB $16.11
  • SLND $4.90
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 81.64
  • SLND 56.86
  • Support Level
  • YMAB $4.16
  • SLND $3.87
  • Resistance Level
  • YMAB $8.54
  • SLND $4.67
  • Average True Range (ATR)
  • YMAB 0.24
  • SLND 0.21
  • MACD
  • YMAB 0.47
  • SLND -0.00
  • Stochastic Oscillator
  • YMAB 99.32
  • SLND 75.00

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About SLND Southland Holdings Inc.

Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.

Share on Social Networks: